Mitoxantrone: benefits and risks in multiple sclerosis patients
- 333 Downloads
Mitoxantrone (MTX) is a synthetic antineoplastic cytotoxic drug, active both on proliferative and non-proliferative cells. The efficacy of MTX has been suggested by many open-label or observational studies and demonstrated in four randomized controlled clinical trials (RCTs). It is indicated for reducing neurological disability and the frequency of clinical relapses in patients with progressive relapsing and worsening relapsing–remitting MS patients. The short-term most frequent adverse events observed in RCTs have been nausea/vomiting, alopecia, an increased risk of urinary and respiratory tract infections, phlebitis, transitory leukopenia, amenorrhea in female patients and infertility. However, the most serious risks of the drug are represented by potential cardiotoxicity and leukaemia, whose incidence seems to be higher than previously reported. Therefore, all potential serious adverse events should be carefully considered against the potential relevant benefits of MTX treatment on every single MS patient.
KeywordsMitoxantrone Multiple sclerosis Adverse events Leukaemia
Conflict of interest statement
The authors declare that they have no conflict of interest related to the publication of this article.
- 5.Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C et al (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112–118CrossRefPubMedGoogle Scholar
- 7.Martinelli Boneschi F, Rovaris M, Capra R, Comi G. (2005) Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev (4):CD002127Google Scholar
- 11.Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G (2008) Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 79(1):52–56CrossRefPubMedGoogle Scholar
- 15.Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, Guerci A, Gratecos N, Rayon C, San Miguel J, Odriozola J, Cahn JY, Huguet F, Vekhof A, Stamatoulas A, Dombret H, Capote F, Esteve J, Stoppa AM, Fenaux P (2003) Therapy-related acute promyelocytic leukaemia. J Clin Oncol 21(11):2123–2137CrossRefPubMedGoogle Scholar
- 18.Le Page E, Leray E, Brochet B et al (2006) Long term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: final report. ECTRIMS Madrid, September 2006, abstract Multiple SclerosisGoogle Scholar
- 19.Ellis RJ, Boggild M (2009)Therapy-related acute leukemia with mitoxantrone: what is the risk and can we minimize it? Mult Scler 15(4):505–508Google Scholar
- 20.Rammohan K, Kita M, Lynn J, Dawson D, Bennet R, AL-Sabbagh A (2008) Post-marketing reports of acute leukemia in mitoxantrone-treated multiple sclerosis patients. Mult Scler 14:S175Google Scholar
- 21.Martinelli V, Amato MP, Bellantonio P (2008) Incidence of acute leukaemia in multiple sclerosis patients treated with mitoxantrone. Neurol Sci Suppl 29:S75Google Scholar